Division of Medical Oncology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey.
Chemotherapy. 2012;58(3):233-40. doi: 10.1159/000339493. Epub 2012 Jul 25.
The administration of the de Gramont regimen in combination with cisplatin and epirubicin (modified ECF) has previously been reported as a treatment for advanced gastric cancer, but here we report this regimen combination in an adjuvant setting for the first time.
Forty-eight patients with curatively resected gastric cancer were treated. Each 2-week cycle consisted of epirubicin (50 mg/m(2)), cisplatin (50 mg/m(2)), 5-fluorouracil (5-FU) IV bolus (400 mg/m(2)) and 5-FU IV (2,400 mg/m(2)) over 46 h plus leucovorin IV (400 mg/m(2)) over 2 h. Postoperative chemoradiotherapy was also administered to the patients when indicated. We retrospectively reviewed the patients who were treated with modified ECF.
The median disease-free survival (DFS) was 40.7 months and the 1-, 3- and 5-year DFS rates were 78.5, 55.7 and 44.6%, respectively. The most common grade 3-4 toxicities were hematological and gastrointestinal.
A modified ECF regimen may be an effective and convenient treatment with tolerable toxicities for the adjuvant treatment of gastric cancer. It may provide an alternative regimen to the standard ECF when a continuous ambulatory infusion pump is not feasible or not preferred by the patient.
含奥沙利铂的 de Gramont 方案联合顺铂和表柔比星（改良 ECF）已被报道用于治疗晚期胃癌，但我们首次在辅助治疗环境中报告了这种方案组合。
48 例可切除的胃癌患者接受了治疗。每个 2 周的周期包括表柔比星（50 mg/m2）、顺铂（50 mg/m2）、5-氟尿嘧啶（5-FU）静脉推注（400 mg/m2）和 5-FU 静脉滴注（2400 mg/m2）持续 46 小时，以及亚叶酸钙（400 mg/m2）静脉滴注 2 小时。当需要时，对患者进行术后放化疗。我们回顾性地分析了接受改良 ECF 治疗的患者。
中位无病生存期（DFS）为 40.7 个月，1、3 和 5 年 DFS 率分别为 78.5%、55.7%和 44.6%。最常见的 3-4 级毒性是血液学和胃肠道毒性。
改良 ECF 方案可能是一种有效且方便的治疗方法，毒性可耐受，可作为标准 ECF 方案的替代方案，适用于不能或不希望使用持续输注泵的患者。
